QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

Core Viewpoint - The law firm Kessler Topaz Meltzer & Check, LLP is investigating potential violations of federal securities laws related to uniQure N.V. following a significant drop in its stock price after the FDA's notification regarding its investigational gene therapy AMT-130 for Huntington's disease [1][2][3]. Group 1: Company Developments - On November 3, 2025, uniQure announced that the FDA indicated the data for its AMT-130 did not provide sufficient evidence to support its Biologics License Application (BLA) submission [2]. - The FDA no longer agrees that data from the Phase I/II studies of AMT-130 may be adequate for the BLA submission, leading to uncertainty regarding the timing of the submission [2]. Group 2: Market Reaction - Following the FDA's announcement, uniQure's stock price plummeted over 50%, dropping from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [3].